staurosporine has been researched along with cabozantinib in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; He, R; Huang, W; Liu, S; Lv, X; Pan, J; Pan, X; Shao, Y; Sun, J; Xi, J; Zhang, J; Zhao, Y; Zhuang, R | 1 |
| Chen, Y; He, H; Liu, M; Qi, B; Wei, F; Yang, Y; Yue, X; Zhang, A; Zhou, X; Zhou, Y | 1 |
| Chen, Y; Gao, L; Li, J; Lu, W; Shen, Q; Tong, L; Zhang, Q | 1 |
| Chen, G; Deng, X; Deng, Z; Dong, C; Hu, Z; Li, L; Li, X; Lian, W; Liu, X; Su, J; Wang, Z; Xu, Q; Yang, Y; Yang, Z; Zhang, B | 1 |
4 other study(ies) available for staurosporine and cabozantinib
| Article | Year |
|---|---|
Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Pyrimidines | 2017 |
Identification of novel N
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Structure-Activity Relationship; Urea | 2018 |
Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine derivatives as new multi-targeted inhibitors of Aurora A/B and KDR.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Azepines; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Humans; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles | 2020 |